Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch
Eli Lilly has received FDA approval for its once-daily oral obesity drug Foundayo (orforglipron), marking the second entry into the oral GLP-1 market after Novo Nordisk's Wegovy. While Wegovy currently holds a dominant position with projected 2026 sales of $11.4 billion, competition is expected to intensify as Foundayo enters the market. Foundayo is forecast to generate around $1.6 billion in revenue in 2026. Wegovy’s sales are anticipated to decline slightly from $12.4 billion in 2025 as market dynamics shift.
- ▪Eli Lilly received FDA approval for Foundayo (orforglipron), a once-daily oral obesity medication, in April 2026.
- ▪Foundayo is the second oral GLP-1 drug approved in the U.S., following Novo Nordisk's oral Wegovy, which launched in January 2026.
- ▪Wegovy is projected to generate $11.4 billion in revenue in 2026, down from $12.4 billion in 2025.
- ▪Foundayo is expected to generate approximately $1.6 billion in revenue in its first full year on the market.
- ▪Increased competition from Eli Lilly is expected to narrow Wegovy's early market lead in the oral GLP-1 space.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Latest Articles","item":"https://seekingalpha.com/latest-articles"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895533-wegovy-early-lead-to-narrow-as-eli-lilly-prepares-foundayo-launch"},"author":{"@type":"Person","name":"Markit","url":"https://seekingalpha.com/author/markit"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
